Buspirone, a 5-HT1A receptor agonist, reduces oxidative stress and protects against CCl4-induced liver fibrosis 370, and portal vein-targeted 5-HT1A modulation has shown promise in reducing portal hypertension 288. This evidence concerns the gene HTR1A and portal hypertension.